Nabi, H, Glintborg, B, Loft, A G, Hendricks, O, Pedersen, J K, Just, S A, Ahmed, R, Danebod, K, Munk, H, Colic, A, Linauskas, A, Jensen, D V, Raun, J, Grydehøj, J, Christensen, L B, Manilo, N, Lomborg, N, Kristensen, S, Mehnert, F, Krogh, N S & Hetland, M 2021, ' Biosimilar to Biosimilar Infliximab Switching in Real-world Patients with Inflammatory Arthritis Followed in the Danish DANBIO Registry: Switch from Originator Infliximab to CT-P13 and Then to GP1111 ', ACR Convergence 2021, 03/11/2021-09/11/2021 pp. 1161-1163 . < https://acrabstracts.org/abstract/biosimilar-to-biosimilar-infliximab-switching-in-real-world-patients-with-inflammatory-arthritis-followed-in-the-danish-danbio-registry-switch-from-originator-infliximab-to-ct-p13-and-then-to-gp1111/ >
Glintborg, B, Sørensen, I J, Loft, A G, Espesen, J, Lindegaard, H, Jensen, D V, Danebod, K, Dieperink, S S, Hendricks, O, Hansen, I M J, Linauskas, A, Kristensen, S, Andersen, L S, Hossein, M, Nordin, H, Andersen, B L, Chrysidis, S, Raun, J L, Manilo, N, Grydehøj, J, Dalgaard, E B, Dalsgaard Pedersen, D, Krogh, N S & Hetland, M L 2017, ' Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up : Results from The DANBIO Registry ', Annals of the Rheumatic Diseases, vol. 76, no. Suppl. 2, FRI0190, pp. 553-554 . < http://ard.bmj.com/content/annrheumdis/76/Suppl_2/553.2.full.pdf >